Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.35 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095954 | 0.93 | SSTR4 (0.35) | RENSSTR4MBTPS1SLC6A2SLC6A4 | |
| SCHEMBL1096262 | 0.88 | REN (0.37) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3576277 | 0.88 | SSTR4 (0.38) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1095974 | 0.87 | CCR5 (0.39) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1095799 | 0.83 | MAPT (0.38) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1097046 | 0.82 | CCR5 (0.37) | RENSSTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1096492 | 0.82 | SSTR4 (0.33) | RENSSTR4MBTPS1SLC6A2SLC6A4 | |
| SCHEMBL1096038 | 0.82 | C5AR1 (0.35) | C5AR1 | |
| SCHEMBL16274994 | 0.82 | REN (0.40) | RENSSTR4 | |
| SCHEMBL3570472 | 0.81 | SSTR4 (0.38) | SSTR4SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | REN 20/4885SSTR4 611/4885MBTPS1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.